Compare JBTM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JBTM | PRAX |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 7.1B |
| IPO Year | 2008 | 2020 |
| Metric | JBTM | PRAX |
|---|---|---|
| Price | $120.21 | $365.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $180.00 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 582.9K | 380.1K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $3,798,200,000.00 | N/A |
| Revenue This Year | $8.10 | N/A |
| Revenue Next Year | $4.68 | $7,758.26 |
| P/E Ratio | $83.93 | ★ N/A |
| Revenue Growth | ★ 121.34 | N/A |
| 52 Week Low | $113.67 | $37.25 |
| 52 Week High | $170.19 | $388.00 |
| Indicator | JBTM | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 36.51 | 60.52 |
| Support Level | $119.46 | $285.26 |
| Resistance Level | $138.34 | $366.52 |
| Average True Range (ATR) | 5.11 | 18.51 |
| MACD | -1.85 | 5.53 |
| Stochastic Oscillator | 16.36 | 76.88 |
JBT Marel Corp operates through two reportable segments: Protein Solutions and Prepared Food and Beverage Solutions. The Protein Solutions segment includes businesses that provide solutions for the initial stage processing and harvesting of animal proteins, mainly focusing on poultry, pork, fish, and beef. The Prepared Food and Beverage Solutions segment includes businesses that offer solutions predominantly for downstream value-added preparation, preservation, and packaging of foods and beverages into ready-to-eat or drink products. This segment will also include capabilities for pet food, dairy, bakery, pharmaceutical, nutraceutical, and warehouse automation end markets. The majority of its revenue is generated from the Prepared Food and Beverage Solutions segment.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.